Our top pick for
Affinity Bancshares Inc is a banks-regional business based in the US. Affinity Bancshares shares (CFBI) are listed on the NASDAQ and all prices are listed in US Dollars. Affinity Bancshares employs 80 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$7.10 - $10.18|
|50-day moving average||$9.96|
|200-day moving average||$8.17|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Affinity Bancshares stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Affinity Bancshares's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Affinity Bancshares's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 39x. In other words, Affinity Bancshares shares trade at around 39x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||$21.9 million|
|Operating margin TTM||24.72%|
|Gross profit TTM||$14.3 million|
|Return on assets TTM||0.33%|
|Return on equity TTM||2.52%|
|Market capitalisation||$76.3 million|
TTM: trailing 12 months
There are currently 10,236 Affinity Bancshares shares held short by investors – that's known as Affinity Bancshares's "short interest". This figure is 49.9% up from 6,830 last month.
There are a few different ways that this level of interest in shorting Affinity Bancshares shares can be evaluated.
Affinity Bancshares's "short interest ratio" (SIR) is the quantity of Affinity Bancshares shares currently shorted divided by the average quantity of Affinity Bancshares shares traded daily (recently around 5532.972972973). Affinity Bancshares's SIR currently stands at 1.85. In other words for every 100,000 Affinity Bancshares shares traded daily on the market, roughly 1850 shares are currently held short.
However Affinity Bancshares's short interest can also be evaluated against the total number of Affinity Bancshares shares, or, against the total number of tradable Affinity Bancshares shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Affinity Bancshares's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Affinity Bancshares shares in existence, roughly 0 shares are currently held short) or 0.0031% of the tradable shares (for every 100,000 tradable Affinity Bancshares shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Affinity Bancshares.
Find out more about how you can short Affinity Bancshares stock.
We're not expecting Affinity Bancshares to pay a dividend over the next 12 months.
Over the last 12 months, Affinity Bancshares's shares have ranged in value from as little as $7.1 up to $10.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Affinity Bancshares's is -0.0406. This would suggest that Affinity Bancshares's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Affinity Bancshares has bucked the trend.
Community First Bancshares, Inc. operates as the holding company for Newton Federal Bank that provides various banking products and services in the United States. The company offers various deposit accounts, including checking accounts, savings accounts, and certificate of deposit accounts. It also provides one-to four-family residential real estate loans, commercial real estate loans, commercial and industrial loans, construction and land loans, indirect automobile loans, and consumer loans, such as loans secured by deposit accounts, loans on new and used automobiles, and unsecured personal loans, as well as multi-family residential real estate loans, and home equity loans and lines of credit. In addition, the company invests in securities; and offers money transfer and other banking services. It operates through its main and branch office in Covington, Georgia; and loan production offices in Watkinsville and Braselton, Georgia. The company was founded in 1928 and is headquartered in Covington, Georgia.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.